The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

The Role of Bevacizumab in Treatment of Metastatic Cervical Cancer

Bradley Monk, MD
Published Online:4:38 PM, Tue November 12, 2013
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Clinical Pearls

  • The recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer
  • Adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%
  • Metastatic cervical cancer was previously though to be resistant to chemotherapy
  • The FDA will be interested in these data, though it remains to be seen if approval will follow
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.